NICE Invites Pharma to Start the Conversation Early, with a View Towards Shifting Away from ‘No’ as the Starting Point

A brief history of NICE CBPartners’ take: The ultimate goal for both parties (manufacturers and NICE) is timely market access for patients as well as a return on investment. To achieve this there will need to be closer collaboration between both parties prior to receiving a recommendation about a new…

The Impact of Central and Eastern European (CEE) International Reference Pricing (IRP) Policy Changes

Summary The Central and Eastern Europe (CEE) region is attractive to drug manufacturers for its large cumulative population, evolving price and market access (P&MA) landscape, and relatively high willingness-to-pay (WTP) thresholds International Reference Pricing (IRP) policies continues to be one of the most important criteria in price decision-making in CEE…

Central Nervous System (CNS) Drug Development Strategy: What is the Role of External Investment in this High-Risk Disease Space?

SUMMARY In 2018, Pfizer announced its plan to stop R&D activity in the central nervous system disease space and to create a venture fund that will invest in biotech firms conducting innovative neuroscience research The strategy of investing in a therapeutic space exclusively via corporate capital is coming into greater…

Applying Technology in Pharma (ATP): Assessment of Investment Trends in Digital Health

SUMMARY VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves Most of these VC-backed digital healthcare companies aim to provide technology-enhanced solutions for providers and patients with…

Page 1 of 8123...Last »